Novartis is spinning off its Sandoz business 25-Aug-2022 By Jane Byrne The Swiss pharma giant wants to turn its biosimilar and generics division into a standalone company.
Will Biden backed bills boost biosimilars uptake in the US? 07-May-2021 By Jane Byrne Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.
UPDATE Industry in conflict over generic and biosimilar manufacturing waiver 22-Jan-2019 By Ben Hargreaves European generics industry faces opposition while pushing for the SPC manufacturing waiver to be altered so it allows for the production of drugs under patent for non-EU countries.
Infographic: Record year for ANDA approvals in US 26-Oct-2018 By Maggie Lynch The US FDA reached a record number of generic ANDAs last financial year, ending September 2018.